PropertyValue
?:abstract
  • Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ\'s use as prophylaxis or treatment for COVID-19, especially in the Indian context.
?:creator
?:doi
  • 10.4103/ijph.ijph_496_20
?:doi
?:journal
  • Indian_journal_of_public_health
?:license
  • cc-by-nc-sa
?:pmid
?:pmid
  • 32496241
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
?:type
?:year
  • 2020-06-01

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/9eo0leey>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/9eo0leey>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all